The Weekly Summary

FriedenOctober 13th – October 19th

In the general news, British Parliament voted to recognize the Palestinian state. The nurse in Spain and two in the U.S. infected with Ebola recovered, as the CDC was profoundly criticized for poor handling of the scare. The stock markets reacted by selling off 10%. In media, HBO and CBA announced a de-bundling plan that would sell their products on the Internet, meaning a quicker end to cable TV.

In healthcare business news, earning began with JNJ posting strong drug revenue. The Abbvie (ABBV) and Shire inversion merger was cancelled. Steris (STE) acquired Britain’s Synergy Health for $1.9 Billion for the inversion tax benefits. Lastly, Mankind (MNKD) reaped a $150 Million milestone on Afrezza, sending the stock up 16%.

On the data front, Regeneron’s (REGN) Eylea outperformed Roche’s Avastin and Lucentis in diabetics. Alnylam (ALNY) posted 6-month data on Patisiran to treat rare Familial Amyloidotic Polyneuropathy.Lastly, NewLink Genetics (NLNK) tested an Ebola vaccine.

From the FDA, Roche’s Esbriet and Boehringer Ingelheim’s Ofev were approved to treat idiopathic pulmonary fibrosis. Also, a panel voted to keep the black box warnings on Pfizer’s (PFE) Chantix.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.